|
MechanismGnRHR antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.United States |
First Approval Date25 Nov 2003 |
Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
100 Clinical Results associated with Speciality European Pharma Ltd. /Private Group/
0 Patents (Medical) associated with Speciality European Pharma Ltd. /Private Group/
100 Deals associated with Speciality European Pharma Ltd. /Private Group/
100 Translational Medicine associated with Speciality European Pharma Ltd. /Private Group/